Enveric Biosciences Q2 net loss $2.5M; EB-003 dual mechanism disclosed, IND on track for early 2026

Enveric Biosciences, Inc.

2025-Q2 EPS reported -$2.15

Net loss $2.5M ($0.97/shr) vs $1.9M ($3.72/shr) in Q2 2024; cash $2.8M at June 30.
Raised $4.9M net proceeds in first half 2025 via financing tools.
EB-003 reveals dual agonism at 5-HT2A (partial) and 5-HT1B receptors, a novel class.
IND submission for EB-003 expected early 2026; preclinical models show PTSD and depression efficacy.
Expanded IP portfolio: new patent filed, allowance for mescaline-derivative and tryptamine patents.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.